A stimulating paper for anyone who works in, or works with, a bio-medical start-up company. The author's summary of their paper is as follows:
- Start-ups are widely accepted as key vehicles of innovation and disruption in healthcare, positioned to make revolutionary discoveries.
- Most of the highest valued start-ups in healthcare have a limited or non-existent participation and impact in the publicly available scientific literature.
- The system of peer-reviewed publishing, while imperfect, is indispensable for validating innovative products and technologies in biomedicine.
- Healthcare products not subjected to peer-review but rather based on internal data generation alone may be problematic and non-trustworthy.